Literature DB >> 779631

Inhibition of potentially pathogenic yeastlike fungi by clotrimazole in combination with 5-fluorocytosine or amphotericin B.

W H Beggs, G A Sarosi, N M Steele.   

Abstract

Clotrimazole (CTM) has a doubtful future with respect to use in treatment of the systemic mycoses. To assess the potential of CTM in combined drug regimens, antifungal effects of CTM together with 5-fluorocytosine (5-FC) or amphotericin B (AMB) were tested in a synthetic liquid medium against Candida albicans, Candida tropicalis, and Torulopsis glabrata. Viable counts were monitored over a 48-h incubation period. Weak inhibitory concentrations of CTM were tested in combination with levels of 5-FC or AMB that alone produced transient antifungal effects followed by rapid recovery of proliferative capacity. Results were similar for each of the organisms studied. Between 24 and 48 h, when cultures containing 5-FC or AMB alone were in the recovery phase, CTM plus 5-FC and CTM plus AMB continued to markedly suppress cell multiplication. It would appear that weak inhibitory concentrations of CTM can act together with 5-FC or AMB to produce antifungal effects greater than that obtained with either of the latter two drugs alone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 779631      PMCID: PMC429640          DOI: 10.1128/AAC.9.6.863

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  New drugs for the systemic mycoses: flucytosine and clotrimazole.

Authors:  J P Utz
Journal:  Bull N Y Acad Med       Date:  1975-10

2.  Clinical studies with oral clotrimazole.

Authors:  H Weuta
Journal:  Postgrad Med J       Date:  1974-07       Impact factor: 2.401

Review 3.  The use of combinations of antimicrobial drugs.

Authors:  E Jawetz
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

4.  [Experimental findings on a new, orally active broad-spectrum antimycotic agent].

Authors:  M Plempel; K Bartmann; K H Büchel; E Regel
Journal:  Dtsch Med Wochenschr       Date:  1969-06-27       Impact factor: 0.628

5.  Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole.

Authors:  P D Hoeprich; A C Huston
Journal:  J Infect Dis       Date:  1975-08       Impact factor: 5.226

6.  Laboratory assessment of the antimycotic drug clotrimazole.

Authors:  R J Holt; R L Newman
Journal:  J Clin Pathol       Date:  1972-12       Impact factor: 3.411

7.  In vitro antifungal activity of clotrimazole (Bay b 5097).

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1971-08       Impact factor: 3.441

8.  Chemotherapeutic evaluation of clotrimazole (Bay b 5097, 1 (o-chloro- - -diphenylbenzyl) imidazole).

Authors:  J A Waitz; E L Moss; M J Weinstein
Journal:  Appl Microbiol       Date:  1971-11

9.  Clotrimazole (Bay b 5097): in vitro and clinical pharmacological studies.

Authors:  M A Burgess; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1972-12       Impact factor: 5.191

10.  In vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Appl Microbiol       Date:  1969-06
  10 in total
  11 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Multifactorial analysis of effects of interactions among antifungal and antineoplastic drugs on inhibition of Candida albicans growth.

Authors:  M A Ghannoum; M S Motawy; M A Abu Hatab; A S Ibrahim; R S Criddle
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

3.  Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.

Authors:  Anders Lignell; Elisabeth Löwdin; Otto Cars; Dominique Sanglard; Jan Sjölin
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

4.  Assay of fluconazole by megabore capillary gas-liquid chromatography with nitrogen-selective detection.

Authors:  S C Harris; J E Wallace; G Foulds; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

5.  Effect of ketoconazole and amphotericin B on encapsulated and non-encapsulated strains of Cryptococcus neoformans.

Authors:  D Smith; H W McFadden; N G Miller
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

6.  Therapy of fungal infections.

Authors:  D J Drutz
Journal:  Bull N Y Acad Med       Date:  1982-11

7.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

8.  Combined activity of ketoconazole and 5-fluorocytosine on potentially pathogenic yeasts.

Authors:  W H Beggs; G A Sarosi
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

Review 9.  Drug resistance in human pathogenic fungi.

Authors:  K Iwata
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

10.  Activity of 2,4-diaminoquinazoline compounds against Candida species.

Authors:  R A Castaldo; D W Gump; J J McCormack
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.